Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael Valladares

Gastroenterology Miami, FL Doctor of Osteopathy

NPI 1407167430 CMS profile 63111

11440 N Kendall Drive, Suite 306, Miami, FL 33176

Open in the dashboard

General payments

$12,863

628 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michael Valladares of Miami, FL is reported in the CMS Open Payments database as having received $12,863 across 628 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,716 76
2024 General $2,980 86
2023 General $1,965 114
2022 General $1,733 100
2021 General $2,226 113
2020 General $1,047 59
2019 General $1,196 80

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Valladares
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Michael Valladares were reported at $1,716. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Michael Valladares Gastroenterology median Middle half National median
2019 $1,196 $417 $126–$1,100 $163
2020 $1,047 $224 $74–$624 $114
2021 $2,226 $352 $106–$1,054 $132
2022 $1,733 $448 $129–$1,270 $149
2023 $1,965 $533 $150–$1,390 $160
2024 $2,980 $605 $160–$1,606 $164
2025 $1,716 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Salix Pharmaceuticals, a division of Bausch Health US, LLC $1,905 169 payments
  2. AbbVie, Inc. $1,771 101 payments
  3. Phathom Pharmaceuticals, Inc. $1,594 16 payments
  4. Janssen Biotech, Inc. $1,189 55 payments
  5. QOL Medical, LLC $1,073 61 payments
  6. Ardelyx, Inc. $684 37 payments
  7. Romark Laboratories, LC $490 12 payments
  8. Genzyme Corporation $400 13 payments
  9. Braintree Laboratories, Inc. $343 16 payments
  10. Nestle HealthCare Nutrition Inc. $300 20 payments
  11. Other $3,115 128 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $11,380 619 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,075 1 payment
  3. Education $380 7 payments
  4. Consulting Fee $28 1 payment
Products named General payments · program years 2019–2025
  1. XIFAXAN $1,519 124 payments
  2. VOQUEZNA $1,387 6 payments
  3. STELARA $1,056 43 payments
  4. IBSRELA $684 37 payments
  5. LINZESS $550 35 payments
  6. ALINIA Gastroenterology $490 12 payments
  7. ALINIA Gastroenterology $490 12 payments
  8. ALINIA Gastroenterology $490 12 payments
  9. Sucraid $467 27 payments
  10. RINVOQ $442 25 payments
  11. Other $7,190 379 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

803

Median for Gastroenterology: 569

Drug cost

$223,025

Median for Gastroenterology: $104,976

Branded share of claims

48.7%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Sucraid Sacrosidase Brand 16 $133,405
Xifaxan Rifaximin Brand 13 $34,584
Linzess Linaclotide Brand 31 $19,817
Clenpiq Sod Picosulf/Mag Ox/Citric Ac Brand 78 $13,349
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 72 $4,466
Sutab Sod Sulf/Pot Chloride/Mag Sulf Brand 19 $3,269
Mesalamine Generic 11 $2,693
Dexlansoprazole Dr Dexlansoprazole Brand 19 $2,608
Cholestyramine Cholestyramine (With Sugar) Brand 20 $2,227
Omeprazole Generic 271 $2,216

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 32 billing codes

Paid by Medicare

$56,523

Medicare's payments for the services billed

Medicare patients

215

Average age 75

Services billed

671

118 women, 97 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 50%
Arthritis 45%
Chronic kidney disease 44%
Depression 42%
Ischemic heart disease 41%
Heart failure 40%
Alzheimer's or dementia 39%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $1,516
$1,516 — —
Sucraid
  • QOL Medical, LLC $246
$246 16 —
STELARA
  • Janssen Biotech, Inc. $239
$239 — —
IBSRELA
  • Ardelyx, Inc. $110
$110 — —
LINZESS
  • Ironwood Pharmaceuticals, Inc $74
  • AbbVie, Inc. $26
$100 31 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

628 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record